In vivo Effects of Abused ‘Bath Salt’ Constituent 3,4-methylenedioxypyrovalerone (MDPV) in Mice: Drug Discrimination, Thermoregulation, and Locomotor Activity

被引:0
作者
William E Fantegrossi
Brenda M Gannon
Sarah M Zimmerman
Kenner C Rice
机构
[1] College of Medicine,Department of Pharmacology and Toxicology
[2] University of Arkansas for Medical Sciences,undefined
[3] Drug Design and Synthesis Section,undefined
[4] Chemical Biology Research Branch,undefined
[5] NIDA and NIAAA,undefined
来源
Neuropsychopharmacology | 2013年 / 38卷
关键词
designer drug; cathinone; behavior; thermoregulation; locomotor activity;
D O I
暂无
中图分类号
学科分类号
摘要
In recent years, synthetic analogues of naturally occurring cathinone have emerged as psychostimulant-like drugs of abuse in commercial ‘bath salt’ preparations. 3,4-Methylenedioxypyrovalerone (MDPV) is a common constituent of these illicit products, and its structural similarities to the more well-known drugs of abuse 3,4-methylenedioxymethamphetamine (MDMA), and methamphetamine (METH) suggest that it may have similar in vivo effects to these substances. In these studies, adult male NIH Swiss mice were trained to discriminate 0.3 mg/kg MDPV from saline, and the interoceptive effects of a range of substitution doses of MDPV, MDMA, and METH were then assessed. In separate groups of mice, surgically implanted radiotelemetry probes simultaneously monitored thermoregulatory and locomotor responses to various doses of MDPV and MDMA, as a function of ambient temperature. We found that mice reliably discriminated the MDPV training dose from saline and that cumulative doses of MDPV, MDMA, and METH fully substituted for the MDPV training stimulus. All three drugs had similar ED50 values in this procedure. Stimulation of motor activity was observed following administration of a wide range of MDPV doses (1–30 mg/kg), and the warm ambient temperature potentiated motor activity and elicited profound stereotypy and self-injurious behavior at 30 mg/kg. In contrast, MDPV-induced hyperthermic effects were observed in only the warm ambient environment. This pattern of effects is in sharp contrast to MDMA, where ambient temperature interacts with thermoregulation, but not locomotor activity. These studies suggest that although the interoceptive effects of MDPV are similar to those of MDMA and METH, direct effects on thermoregulatory processes and locomotor activity are likely mediated by different mechanisms than those of MDMA.
引用
收藏
页码:563 / 573
页数:10
相关论文
共 250 条
[1]  
Baumann MH(2012)The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37 1192-1203
[2]  
Ayestas MA(2012)Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products Neuropsychopharmacology 38 552-562
[3]  
Partilla JS(2012)Hyperthermia and multiorgan failure after abuse of ‘bath salts’ containing 3,4-methylenedioxypyrovalerone Ann Emerg Med 60 103-105
[4]  
Sink JR(1996)Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion Biochem Pharmacol 51 789-796
[5]  
Shulgin AT(1994)Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) in rats Psychopharmacology (Berl) 114 505-508
[6]  
Daley PF(1997)Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs Pharmacol Biochem Behav 58 1109-1116
[7]  
Baumann Michael H(2000)Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans Br J Clin Pharmacol 49 104-109
[8]  
Partilla John S(2012)The pemoline model of self-injurious behaviour Methods Mol Biol 829 155-163
[9]  
Lehner Kurt R(2008)A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse Neuroscience 151 533-543
[10]  
Thorndike Eric B(2009)Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations J Pharmacol Exp Ther 329 1006-1015